Article Text

Download PDFPDF
Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
  1. Michael G. Kelly, MD*,
  2. Gil Mor, PhD, MD,
  3. Alan Husband, PhD,
  4. David M. O'Malley, MD§,
  5. Lisa Baker, RN,
  6. Masoud Azodi, MD,
  7. Peter E. Schwartz, MD and
  8. Thomas J. Rutherford, PhD, MD
  1. * Division of Gynecology Oncology, University of Colorado School of Medicine, Denver, CO;
  2. Division of Gynecology Oncology, Yale University School of Medicine, New Haven, CT;
  3. Faculty of Veterinary Science, University of Sydney, Sydney, Australia; and
  4. § Department of Obstetrics and Gynecology, Ohio State University, Columbus, OH.
  1. Address correspondence and reprint requests to Michael G. Kelly, MD, Academic Office One, Room 4412, 12631 E 17th Ave, MS B198-4; PO Box 6511, Aurora, CO 80045; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06511. E-mail: Michael.Kelly{at}


Introduction: Chemoresistance is a major limitation in the treatment of ovarian cancer. Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo. In this study, we determined the safety and efficacy of intravenous phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant ovarian cancers.

Methods: Thirty-two patients were randomized to 1 of 2 treatment arms according to their previous responses: (1) platinum refractory/resistant, cisplatin (40 mg/m2 intravenous) weekly on day 2 + phenoxodiol (3 mg/kg) weekly on days 1 and 2 and (2) taxane refractory/resistant, paclitaxel (80 mg/m2 IV) weekly on day 2 and phenoxodiol (3 mg/kg) weekly on days 1 and 2. Patients continued on treatment until complete response, disease progression, unacceptable toxicity, or voluntary withdrawal.

Results: There were no treatment-related deaths. There was only one treatment-related hospitalization and 2 grade 4 toxicities. In the cisplatin arm, there were 3 partial responses, 9 patients (56%) achieved stable disease, 4 (25%) progressed, and the overall best response rate was 19%. In the paclitaxel arm, there was one complete response and 2 partial responses, 8 patients (53%) achieved stable disease, 4 patients (27%) progressed, and the overall best response rate was 20%.

Discussion: The combination of IV phenoxodiol with cisplatin or paclitaxel was well tolerated in this study. Cisplatin-phenoxodiol was particularly active and warrants further study in patients with platinum-resistant ovarian cancer.

  • Ovarian cancer
  • Phenoxodiol
  • Chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors have no conflicts of interest.